

FILE 'HOME' ENTERED AT 10:34:05 ON 23 SEP 2002

=> file caplus uspatful europatful japio medline biosis embase		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.84	0.84

FILE 'CAPLUS' ENTERED AT 10:36:19 ON 23 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 10:36:19 ON 23 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 10:36:19 ON 23 SEP 2002
COPYRIGHT (c) 2002 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 10:36:19 ON 23 SEP 2002
COPYRIGHT (C) 2002 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 10:36:19 ON 23 SEP 2002

FILE 'BIOSIS' ENTERED AT 10:36:19 ON 23 SEP 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 10:36:19 ON 23 SEP 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

=> s transmucosal? and (drug delivery)

4 FILES SEARCHED...

L1 1427 TRANSMUCOSAL? AND (DRUG DELIVERY)

=> s l1 and (sequential or two or multiple)(w)phase?

3 FILES SEARCHED...

L2 57 L1 AND (SEQUENTIAL OR TWO OR MULTIPLE)(W) PHASE?

=> s l2 and pH and (modif? or adjust? or neutral? or acid? or bas? or alkali?)

3 FILES SEARCHED...

L3 43 L2 AND PH AND (MODIF? OR ADJUST? OR NEUTRAL? OR ACID? OR BAS?
OR ALKALI?)

=> s l3 and dissol? and absor?

4 FILES SEARCHED...

L4 33 L3 AND DISSOL? AND ABSOR?

=> s l4 and (coat? or membrane# or matri? or precursor?)

3 FILES SEARCHED...

L5 33 L4 AND (COAT? OR MEMBRANE# OR MATRI? OR PRECURSOR?)

=> s l5 qand (buccal? or sublingual? or gingival? or gastrointestinal? or rectal?
or vaginal? or nasal?)

MISSING OPERATOR L5 QAND

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l5 and (buccal? or sublingual? or gingival? or gastrointestinal? or rectal? or
vaginal? or nasal?)

5 FILES SEARCHED...

L6 33 L5 AND (BUCCAL? OR SUBLINGUAL? OR GINGIVAL? OR GASTROINTESTINAL
? OR RECTAL? OR VAGINAL? OR NASAL?)

=> s l6 and local?
L7 25 L6 AND LOCAL?

=> d l7 1-25 ibib abs

L7 ANSWER 1 OF 25 USPATFULL

ACCESSION NUMBER: 2002:243051 USPATFULL
TITLE: Compositions and methods for the therapy and diagnosis
of ovarian cancer
INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132237	A1	20020919
APPLICATION INFO.:	US 2001-867701	A1	20010529 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	25718	

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

L7 ANSWER 2 OF 25 USPATFULL

ACCESSION NUMBER: 2002:199159 USPATFULL
TITLE: Benzoxazole LPAAT-B inhibitors and uses thereof
INVENTOR(S): Bonham, Lynn, Seattle, WA, UNITED STATES
Klein, J. Peter, Vashon, WA, UNITED STATES
Finney, Robert E., Shoreline, WA, UNITED STATES
Hollenback, David M., Seattle, WA, UNITED STATES
Shaffer, Scott A., Seattle, WA, UNITED STATES
Tang, Norina M., Ann Arbor, WA, UNITED STATES
White, Thayer H., Bellevue, WA, UNITED STATES
Leung, David W., Mercer Island, WA, UNITED STATES
PATENT ASSIGNEE(S): CELL THERAPEUTICS, INC.

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002107269	A1	20020808
APPLICATION INFO.:	US 2001-984889	A1	20011031 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244194P	20001031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: Stephen A. Bent, Foley & Lardner, Washington Harbour,
3000 K Street, N.W., Suite 500, Washington, DC,
20007-5109

NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 2653

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to benzoxazoles and the use thereof to inhibit
lysophosphatidic acid acyltransferase .beta. (LPAAT-.beta.)
activity. The invention further relates to methods of treating cancer
using said benzoxazoles. The invention also relates to methods for
screening for LPAAT-.beta. activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 25 USPATFULL

ACCESSION NUMBER: 2002:192124 USPATFULL
TITLE: LPAAT-B inhibitors and uses thereof
INVENTOR(S): Bonham, Lynn, Seattle, WA, UNITED STATES
Klein, J. Peter, Vashon, WA, UNITED STATES
Finney, Robert E., Shoreline, WA, UNITED STATES
Hollenback, David M., Seattle, WA, UNITED STATES
Shaffer, Scott A., Seattle, WA, UNITED STATES
Tang, Norina M., Ann Arbor, MI, UNITED STATES
White, Thayer H., Bellevue, WA, UNITED STATES
Leung, David W., Mercer Island, WA, UNITED STATES
PATENT ASSIGNEE(S): CELL THERAPEUTICS, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002103195	A1	20020801
APPLICATION INFO.:	US 2001-984888	A1	20011031 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244195P	20001031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Stephen A. Bent, Foley & Lardner, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, DC, 20007-5109	

NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 1634

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to triazines and the use thereof to inhibit
lysophosphatidic acid acyltransferase .beta. (LPAAT-.beta.)
activity. The invention further relates to methods of treating cancer
using said triazines. The invention also relates to methods for
screening for LPAAT-.beta. activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 25 USPATFULL

ACCESSION NUMBER: 2002:148306 USPATFULL
TITLE: Multiple phase cross-linked
compositions and uses thereof
INVENTOR(S): Stein, Stanley, East Brunswick, NJ, UNITED STATES
Qiu, Bo, East Brunswick, NJ, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2002076443 A1 20020620
 APPLICATION INFO.: US 2001-883842 A1 20010618 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-212511P	20000619 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KLAUBER & JACKSON, 411 HACKENSACK AVENUE, HACKENSACK, NJ, 07601	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1908	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to pharmaceutical compositions, and method for preparing pharmaceutical compositions, comprising a cross-linked **matrix** physically entrapping at least one therapeutic agent. The **matrix** may comprise one or more phases in addition to an aqueous phase, such as a solid and/or oil phase. The **matrix** of the invention has at least one controlled release in-vivo kinetic profile, and may have additional profiles for the same agent. The **matrix** may also comprise more than one therapeutic agent, and each additional therapeutic agent may have one or more controlled release in-vivo kinetic profile.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 25 USPATFULL
 ACCESSION NUMBER: 2002:63527 USPATFULL
 TITLE: Hydrophilic ampholytic polymer
 INVENTOR(S): Galleguillos, Ramiro, Hudson, OH, United States
 Budrevich, Jodi A., Cuyahoga Falls, OH, United States
 Chiarelli, Joseph A., Broadview Heights, OH, United States
 Bathina, Harinath B., Hudson, OH, United States
 Amjad, Zahid, Brecksville, OH, United States
 PATENT ASSIGNEE(S): PMD Holdings Corp., Brecksville, OH, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6361768	B1	20020326
APPLICATION INFO.:	US 1998-222495		19981229 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Sheikh, Humera N.		
LEGAL REPRESENTATIVE:	Moxon, II, George W., Hudak & Shunk Co., L.P.A.		
NUMBER OF CLAIMS:	54		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	2061		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel hydrophilic ampholytic polymer synthesized by reacting polymerizable amino and carboxy functional ethylenically unsaturated monomers, together with a non-ionic hydrophilic monomer, to provide a polymer having a glass transition temperature (T.sub.g) above about 50.degree. C., and optionally hydrophobic monomer(s), and cross-linking monomer(s). The copolymer is precipitated from a polymerization media which includes a suitable organic solvent. The resulting copolymer is in the form of a fine powder, with submicron particle size. As such it is suitable for use as a thickener or rheology modifier in personal care formulations, such as shampoo, conditioner, and the like,

as a bioadhesive, and for other pharmaceutical applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 25 USPATFULL

ACCESSION NUMBER: 2002:60703 USPATFULL

TITLE: Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites

INVENTOR(S): Schulze, Brita, Walchensee, GERMANY, FEDERAL REPUBLIC OF
Sauer, Birgitta, Penzberg, GERMANY, FEDERAL REPUBLIC OF
Dellian, Marc, Munich, GERMANY, FEDERAL REPUBLIC OF
Michaelis, Uwe, Weilheim, GERMANY, FEDERAL REPUBLIC OF
Teifel, Michael, Penzberg, GERMANY, FEDERAL REPUBLIC OF
Naujoks, Kurt W., Penzberg, GERMANY, FEDERAL REPUBLIC OF
Biro, Claudia, Muehldorf, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002034537	A1	20020321
APPLICATION INFO.:	US 2001-847538	A1	20010503 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201673P	20000503 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN, LEWIS & BOCKIUS, 1800 M STREET NW, WASHINGTON, DC, 20036-5869	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	2561	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and associated compositions are described for enhancing the selective delivery of therapeutic, diagnostic and imaging agents to activated vascular sites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 25 USPATFULL

ACCESSION NUMBER: 2002:32528 USPATFULL

TITLE: Targeted angiogenesis

INVENTOR(S): Levine, Arnold J., New York, NY, UNITED STATES
Mitterer, Artur, Orth, Donau, AUSTRIA
Falkner, Falko-Guenter, Orth, Donau, AUSTRIA
Scheifflinger, Friedrich, Vienna, AUSTRIA
Dorner, Friedrich, Vienna, AUSTRIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019350	A1	20020214
APPLICATION INFO.:	US 2001-782650	A1	20010212 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-327045, filed on 7 Jun 1999, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2479		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compositions, methods, and gene therapy reagents to promote or to inhibit angiogenesis in the treatment of peripheral vascular or cardiovascular diseases, utilizing a chimeric molecule comprising an angiogenic factor linked to a targeting molecule that specifically binds to a vascular endothelium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 25 USPATFULL

ACCESSION NUMBER: 2002:21845 USPATFULL
TITLE: Compositions and methods for improved delivery of lipid regulating agents
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002012680	A1	20020131
	US 6451339	B2	20020917
APPLICATION INFO.:	US 2001-898553	A1	20010702 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025		
NUMBER OF CLAIMS:	140		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	3604		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to triglyceride-free pharmaceutical compositions for delivery of hydrophobic therapeutic agents. Compositions of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the surfactants containing the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 25 USPATFULL

ACCESSION NUMBER: 2001:237457 USPATFULL
TITLE: **Nasal drug delivery**
composition
INVENTOR(S): Davis, Stanley Stewart, Nottingham, Great Britain
Illum, Lisbeth, Nottingham, Great Britain
PATENT ASSIGNEE(S): West Pharmaceutical Services Drug Delivery & Clinical Research Centre, Ltd (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001055569	A1	20011227
APPLICATION INFO.:	US 2001-841228	A1	20010424 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-GB3489, filed on 21 Oct 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-23246	19981024
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE
SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA,
PA, 19103

NUMBER OF CLAIMS: 14

EXEMPLARY CLAIM: 1

LINE COUNT: 397

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a composition comprising an oil-in-water
emulsion and a drug **dissolved** in the emulsion. The oil phase
comprises a hydroxylated oil, particularly a hydroxylated vegetable oil.
The preferred hydroxylated vegetable oil is castor oil.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 25 USPATFULL

ACCESSION NUMBER: 2001:217985 USPATFULL

TITLE: Infrared thermography and methods of use

INVENTOR(S): Marek, Przemyslaw A., Bolton, MA, United States
Trocha, Andzrej M., Billerica, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001046471	A1	20011129
APPLICATION INFO.:	US 2001-850081	A1	20010508 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-202935P	20000509 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EDWARD D GRIEFF, HALE & DORR LLP, 1455 PENNSYLVANIA AVE, NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	99	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	2687	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes rapid noninvasive methods for measuring
vasodilation or changes in blood flow in a patient following
administration of at least one compound that donates, transfers or
releases nitric oxide, elevates endogenous levels of endothelium-derived
relaxing factor, stimulates endogenous synthesis of nitric oxide or is a
substrate for nitric oxide synthase and/or at least one vasoactive
agent. The method comprises the administration of at least one compound
that donates, transfers or releases nitric oxide, elevates endogenous
levels of endothelium-derived relaxing factor, stimulates endogenous
synthesis of nitric oxide or is a substrate for nitric oxide synthase
and/or at least one vasoactive agent to the patient followed by
monitoring the temperature change of an area of interest using infrared
thermography. The present invention provides methods for diagnosing
diseases or disorders related to vasodilation and changes in blood flow,
such as, sexual dysfunction, Raynaud's syndrome, inflammation,
hypertension, **gastrointestinal** disorders and central nervous
system disorders. The sexual dysfunction is preferably female sexual
dysfunction and female sexual arousal. The vasoactive agents include
potassium channel activators, calcium channel blockers,
.alpha.-adrenergic receptor antagonists, .beta.-blockers,
phosphodiesterase inhibitors, adenosine, ergot alkaloids, vasoactive
intestinal peptides, prostaglandins, dopamine agonists, opioid
antagonists, endothelin antagonists and thromboxane inhibitors. The
present invention can also be used to screen and identify drug
candidates for treating diseases, disorders and conditions resulting
from vasodilation or changes in blood flow. The present invention also
describes compositions comprising at least one S-nitrosothiol compound

solid solution with a **dissolution** agent. The formulation is administered into a patient's oral cavity, delivering the pharmaceutical agent by **absorption** through a patient's oral mucosal tissue. The formulation and method provide for improved oral mucosal delivery of the pharmaceutical agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 25 USPATFULL

ACCESSION NUMBER: 2001:93139 USPATFULL
TITLE: Metal/thiol biocides
INVENTOR(S): Domenico, Philip, Elmhurst, NY, United States
PATENT ASSIGNEE(S): Winthrop University Hospital, Mineola, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6248371	B1	20010619
APPLICATION INFO.:	US 2000-543880		20000406 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-960031, filed on 28 Oct 1997, now patented, Pat. No. US 6086921 Continuation-in-part of Ser. No. US 1997-883584, filed on 26 Jun 1997, now patented, Pat. No. US 5928671 Continuation of Ser. No. US 1995-428464, filed on 25 Apr 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Spivack, Phyllis G.		
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen, LLP		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	2322		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for administering a composition comprising bismuth and a thiol-containing complexing agent as a bacteriocidal, bacteriostatic, antifungal or antiviral agent are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 25 USPATFULL

ACCESSION NUMBER: 2001:36919 USPATFULL
TITLE: Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
INVENTOR(S): Rathi, Ramesh C., Salt Lake City, UT, United States
Zentner, Gaylen M., Salt Lake City, UT, United States
Jeong, Byeongmoon, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): MacroMed, Inc., Sandy, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6201072	B1	20010313
APPLICATION INFO.:	US 1999-396589		19990915 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-164865, filed on 1 Oct 1998, now patented, Pat. No. US 6117949 Continuation-in-part of Ser. No. US 1997-943167, filed on 3 Oct 1997, now patented, Pat. No. US 6004573		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Truong, Duc		
LEGAL REPRESENTATIVE:	Thorpe North & Western LLP		
NUMBER OF CLAIMS:	77		

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A water soluble, biodegradable ABA- or BAB-type tri-block polymer is disclosed that is made up of a major amount of a hydrophobic A polymer block made of a biodegradable polyester and a minor amount of a hydrophilic polyethylene glycol (PEG) B polymer block, having an overall average molecular weight of between about 2000 and 4990, and that possesses reverse thermal gelation properties. Effective concentrations of the tri-block polymer and a drug may be uniformly contained in an aqueous phase to form a **drug delivery** composition. At temperatures below the gelation temperature of the tri-block polymer the composition is a liquid and at temperatures at or above the gelation temperature the composition is a gel or semi-solid. The composition may be administered to a warm-blooded animal as a liquid by parenteral, ocular, topical, inhalation, transdermal, **vaginal**, transurethral, **rectal**, **nasal**, oral, pulmonary or aural delivery means and is a gel at body temperature. The composition may also be administered as a gel. The drug is released at a controlled rate from the gel which biodegrades into non-toxic products. The release rate of the drug may be **adjusted** by changing various parameters such as hydrophobic/hydrophilic component content, polymer concentration, molecular weight and polydispersity of the tri-block polymer. Because the tri-block polymer is amphiphilic, it functions to increase the solubility and/or stability of drugs in the composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 25 USPATFULL
ACCESSION NUMBER: 2000:121592 USPATFULL
TITLE: Biodegradable low molecular weight triblock poly
(lactide-co-glycolide) polyethylene glycol copolymers
having reverse thermal gelation properties
INVENTOR(S): Rathi, Ramesh C., Salt Lake City, UT, United States
Zentner, Gaylen M., Salt Lake City, UT, United States
Jeong, Byeongmoon, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Macromed, Inc., Salt Lake City, UT, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117949		20000912
APPLICATION INFO.:	US 1998-164865		19981001 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Truong, Duc		
LEGAL REPRESENTATIVE:	Thorpe, North & Western, LLP		
NUMBER OF CLAIMS:	69		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	1274		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A water soluble biodegradable ABA- or BAB-type triblock polymer is disclosed that is made up of a major amount of a hydrophobic polymer made of a poly(lactide-co-glycolide) copolymer or poly(lactide) polymer as the A-blocks and a minor amount of a hydrophilic polyethylene glycol polymer B-block, having an overall weight average molecular weight of between about 2000 and 4990, and that possesses reverse thermal gelation properties. Effective concentrations of the triblock polymer and a drug may be uniformly contained in an aqueous phase to form a **drug delivery** composition. At temperatures below the gelation temperature of the triblock polymer the composition is a liquid and at temperatures at or above the gelation temperature the composition is a

gel or semi-solid. The composition may be administered to a warm-blooded animal as a liquid by parenteral, ocular, topical, inhalation, transdermal, **vaginal**, transurethral, **rectal**, **nasal**, oral, pulmonary or aural delivery means and is a gel at body temperature. The composition may also be administered as a gel. The drug is released at a controlled rate from the gel which biodegrades into non-toxic products. The release rate of the drug may be **adjusted** by changing various parameters such as hydrophobic/hydrophilic component content, polymer concentration, molecular weight and polydispersity of the triblock polymer. Because the triblock polymer is amphiphilic, it functions to increase the solubility and/or stability of drugs in the composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 25 USPATFULL

ACCESSION NUMBER: 2000:87752 USPATFULL
 TITLE: Metal/thiol biocides
 INVENTOR(S): Domenico, Philip, Elmhurst, NY, United States
 PATENT ASSIGNEE(S): Wintrop-University Hospital, Mineola, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6086921		20000711
APPLICATION INFO.:	US 1997-960031		19971028 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-883584, filed on 26 Jun 1997, now patented, Pat. No. US 5928671 which is a continuation of Ser. No. US 1995-428464, filed on 25 Apr 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spivack, Phyllis G.		
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen, LLP		
NUMBER OF CLAIMS:	41		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	2588		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition described wherein bismuth is chelated by a complexing agent such as a pyrithione or certain other thiol compounds in the form a metal:complexing agent complex. Methods for using the composition as a bacteriocidal, bacteriostatic, antibiofilm, antifungal, and antiviral agent and as a disinfectant and preservative are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 25 USPATFULL

ACCESSION NUMBER: 2000:9947 USPATFULL
 TITLE: Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
 INVENTOR(S): Kun, Ernest, Mill Valley, CA, United States
 Mendelejev, Jerome, Tiburon, CA, United States
 PATENT ASSIGNEE(S): Octamer, Inc., Berkeley, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6017958		20000125
APPLICATION INFO.:	US 1997-833272		19970403 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-655267, filed on 4 Jun 1996, now patented, Pat. No. US 5736576		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

PRIMARY EXAMINER: Goldberg, Jerome D.
LEGAL REPRESENTATIVE: Halluin, Albert P. Howrey & Simon
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 2491

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for treating cancer, particularly malignant tumors, with thyroxine analogues having no significant hormonal activity. A thyroxine analogue is administered to an afflicted mammal in an amount effective to cause depression or regression of malignant tumor growth or to treat cancer. Particularly preferred thyroxine analogues are those capable of causing about 35 percent or more inhibition of initial velocity of microtubule protein assembly in vitro.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 25 USPATFULL

ACCESSION NUMBER: 1999:155235 USPATFULL
TITLE: Method for preparing biphasic multilamellar lipid vesicles
INVENTOR(S): Foldvari, Marianna, Saskatoon, Canada
PATENT ASSIGNEE(S): PharmaDerm Laboratories, Ltd., Saskatchewan, Canada
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5993851		19991130
APPLICATION INFO.:	US 1998-42097		19980313 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-872068, filed on 10 Jun 1997 which is a continuation of Ser. No. US 1995-507923, filed on 27 Jul 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-98102, filed on 28 Jul 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kishore, Gollamudi S.		
LEGAL REPRESENTATIVE:	Mohr, Judy M. Dehlinger & Associates		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	2036		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A biphasic multilamellar lipid vesicle comprising a plurality of spaced apart lipid bilayers that include a liposome-forming component and optionally a biologically active agent entrapped within the lipid bilayers. The lipid vesicle also comprises peripheral aqueous solution compartments formed between the lipid bilayers and a central lipophilic core compartment substantially at the center of the multilamellar lipid vesicle.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 25 USPATFULL

ACCESSION NUMBER: 1999:96436 USPATFULL
TITLE: Responsive polymer networks and methods of their use
INVENTOR(S): Bromberg, Lev, Lynn, MA, United States
Lupton, Elmer Cornelius (E.C.), Boston, MA, United States
Schiller, Matthew E., Waltham, MA, United States
Timm, Mary Jo (M.J.), Taunton, MA, United States
McKinney, George, Chestnut Hill, MA, United States
PATENT ASSIGNEE(S): MedLogic Global Corporation, Colorado Springs, CO,

United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5939485		19990817
APPLICATION INFO.:	US 1996-580986		19960103 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-312P	19950619 (60)
	US 1995-8053P	19951030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Lipman, Bernard	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 15 Drawing Page(s)	
LINE COUNT:	2688	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A responsive polymer network exhibiting the property of reversible gelation in response to a change in an environmental stimulus is provided. The aqueous solution of the network polymer, comprises about 0.01 to 20 wt % by weight of a responsive component and about 0.01 to 20 wt % by weight of a structural component capable of supporting and interacting with the responsive component. The aqueous composition exhibits at least a five-fold increase in viscosity upon gelation. The gelation may be triggered by a change in an environmental stimulus, such as temperature, pH and ionic strength.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 25 USPATFULL

ACCESSION NUMBER: 1999:92323 USPATFULL
 TITLE: **Nasal drug delivery**
 composition containing nicotine
 INVENTOR(S): Illum, Lisbeth, The Park, United Kingdom
 PATENT ASSIGNEE(S): Danbiosyst UK Limited, Nottingham, United Kingdom
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5935604		19990810
	WO 9427576		19941208
APPLICATION INFO.:	US 1996-553401		19960701 (8)
	WO 1994-GB1092		19940520
			19960701 PCT 371 date
			19960701 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1993-10412	19930520
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kulkosky, Peter F.	
LEGAL REPRESENTATIVE:	Arnall Golden & Gregory, LLP	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	812	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a **nasal drug delivery** composition comprising nicotine or a pharmacologically-acceptable salt or derivative thereof wherein the

composition is adapted to delivery a pulse of nicotine for rapid **absorption** and a controlled release of nicotine for subsequent sustained **absorption**. The controlled release phase can be achieved by providing an ion-exchange material which will form a complex with the nicotine. The ion-exchange material may be a polymeric material such as a polysaccharide, or may be in the form of bioadhesive ion-exchange microspheres. The pulse release can be achieved by overloading the ion-exchange material with nicotine so that the composition contains some excess nicotine for immediate release and **absorption**. Alternatively, some nicotine may be associated with a non ion-exchange material which will release the nicotine immediately on contact with the **nasal** mucosa, for example non-ion-exchange bioadhesive microspheres.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 25 USPATFULL

ACCESSION NUMBER: 1999:60998 USPATFULL
 TITLE: Intra-oral antioxidant preparations
 INVENTOR(S): Hersh, Theodore, Atlanta, GA, United States
 PATENT ASSIGNEE(S): Thione International, Inc., Atlanta, GA, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5906811		19990525
APPLICATION INFO.:	US 1997-884282		19970627 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kulkosky, Peter F.		
LEGAL REPRESENTATIVE:	Wittenberg, Malcolm B.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1356		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The combination of several synergistic antioxidants, enzymatic co-factors and amino acids in appropriate delivery vehicles employed in aerosol carriers, mist and pump oral sprays, solutions, such as oral irrigators, mouth rinses and mouthwashes, or gels and solid compositions as a means of preventing and ameliorating signs and symptoms and complications to the oro-pharyngeal cavity and mouth including **buccal** mucosa, gums and tongue and the upper respiratory tract from damage caused by free radical species induced by tobacco smoke, smokeless tobacco, ingested or chewed noxious, malodorous or harmful substances and other inhaled environmental pollutants and particulate matter, including tobacco to secondary smokers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 25 USPATFULL

ACCESSION NUMBER: 1998:162029 USPATFULL
 TITLE: Biphasic multilamellar lipid vesicles
 INVENTOR(S): Foldvari, Marianna, Saskatoon, Canada
 PATENT ASSIGNEE(S): PharmaDerm Laboratories Ltd., Saskatchewan, Canada
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5853755		19981229
APPLICATION INFO.:	US 1997-872068		19970610 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-507923, filed on 27 Jul 1995, now abandoned And a continuation-in-part of Ser. No. US 1993-98102, filed on 28 Jul 1993, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kishore, Gollamudi S.
LEGAL REPRESENTATIVE: Mohr, Judy M. Dehlinger & Associates
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1938

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A biphasic multilamellar lipid vesicle comprising a plurality of spaced apart lipid bilayers that include a liposome-forming component and optionally a biologically active agent entrapped within the lipid bilayers. The lipid vesicle also comprises peripheral aqueous solution compartments formed between the lipid bilayers and a central lipophilic core compartment substantially at the center of the multilamellar lipid vesicle.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 25 USPATFULL

ACCESSION NUMBER: 90:79697 USPATFULL

TITLE: **Drug delivery** compositions and methods

INVENTOR(S): Ecanow, Bernard, Wilmette, IL, United States

PATENT ASSIGNEE(S): Medaphore, Inc., Wilmette, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4963367		19901016
APPLICATION INFO.:	US 1987-130550		19871215 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1985-711066, filed on 12 Mar 1985, now abandoned And Ser. No. US 1985-710048, filed on 11 Mar 1985, now abandoned And Ser. No. US 1986-835550, filed on 3 Mar 1986, now patented, Pat. No. US 4849405 And Ser. No. US 1986-896844, filed on 14 Aug 1986, now abandoned And Ser. No. US 1987-1314, filed on 8 Jan 1987, now patented, Pat. No. US 4794000 And Ser. No. US 1987-31237, filed on 26 Mar 1987, now patented, Pat. No. US 4914084 And Ser. No. US 1987-54193, filed on 26 May 1987, now abandoned And Ser. No. US 1987-54194, filed on 26 May 1987, now abandoned And Ser. No. US 1985-811675, filed on 20 Dec 1985, now patented, Pat. No. US 4738952 which is a continuation-in-part of Ser. No. US 1984-604476, filed on 27 Apr 1984, now abandoned, said Ser. No. 835550 which is a continuation-in-part of Ser. No. US 1984-604483, filed on 9 May 1984, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lovering, Richard D.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Bicknell
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1,27
LINE COUNT: 2363

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Drug delivery** compositions yeild new and unexpected degrees of stabilization, solubilization and delivery of incorporated medicaments, drugs, or other physiologically-active compounds. The compositions enable administration of drugs and other medically useful compounds via a variety of routes. More particularly, a **drug delivery** system or composition including one or more monomeric or polymerized surface active agents allows for rapid

dissolution and smooth liberation of any desired incorporated drug or combinations, and the method of preparing the drug composition. In one embodiment, the physiologically-active compound is encapsulated by a coacervate-derived film, and the finished product is suitable for **transmucosal** administration. Other formulations of this invention may be administered via inhalation, oral, parenteral and by transdermal and **transmucosal** routes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 25 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 697858 EUROPATFULL EW 199743 FS PS
 TITLE: **NASAL DRUG DELIVERY**
 COMPOSITION CONTAINING NICOTINE.
 ARZNEIMITTELZUSAMMENSETZUNG FUEr VERABREICHUNG VON
 NIKOTIN DURCH DIE NASE.
 COMPOSITION D'ADMINISTRATION PAR VOIE **NASALE**
 D'UN MEDICAMENT, CONTENANT DE LA NICOTINE.
 INVENTOR(S): ILLUM, Lisbeth, 19 Cavendish Crescent North, The Park,
 Nottingham NG7 1BA, GB
 PATENT ASSIGNEE(S): DANBIOSYST UK LIMITED, Albert Einstein Centre,
 Highfields Science Park, Nottingham NG7 2TN, GB
 PATENT ASSIGNEE NO: 1161683
 AGENT: Bassett, Richard Simon et al, ERIC POTTER & CLARKSON St.
 Mary's Court St. Mary's Gate, Nottingham NG1 1LE, GB
 AGENT NUMBER: 52833
 OTHER SOURCE: EPB1997068 EP 0697858 B1 971022
 SOURCE: Wila-EPS-1997-H43-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GR; R IE; R
 IT; R LI; R NL; R PT; R SE
 PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale
 Anmeldung)
 PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 697858	B1	19971022
		19960228
'OFFENLEGUNGS' DATE:		19960228
APPLICATION INFO.:	EP 1994-915637	19940520
PRIORITY APPLN. INFO.:	GB 1993-10412	19930520
RELATED DOC. INFO.:	WO 94-GB1092	940520 INTAKZ
	WO 9427576	941208 INTPNR
REFERENCE PAT. INFO.:	EP 148749 A	WO 93-12764 A
REF. NON-PATENT-LIT.:	Whistler et al. "Industrial Gums" Academic Press (1993), pages 537 and 548-551 Sigma Catalogue (1995), page 1705	

L7 ANSWER 25 OF 25 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 274431 EUROPATFULL EW 198828 FS OS STA B
 TITLE: **Drug delivery** compositions and
 methods.
 Mittel zur Arzneistoffabgabe und Verfahren zu deren
 Herstellung.
 Compositions pour la liberation d'un medicament et leurs
 procedes de fabrication.
 INVENTOR(S): Ecanow, Bernard, 540 Hunter Court, Wilmette Illinois
 60091, US
 PATENT ASSIGNEE(S): MEDAPHORE INC., 540 Hunter Court, Wilmette, IL 60091, US

PATENT ASSIGNEE NO: 397830
 AGENT: Wain, Christopher Paul, et al, A.A. THORNTON & CO.
 Northumberland House 303-306 High Holborn, London WC1V
 7LE, GB
 OTHER SOURCE: ESP1988025 EP 0274431 A2 880713
 SOURCE: Wila-EPZ-1988-H28-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R FR; R GB; R IT; R LI; R NL; R
 SE
 PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
 PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 274431	A2 19880713
'OFFENLEGUNGS' DATE:		19880713
APPLICATION INFO.:	EP 1988-300085	19880107
PRIORITY APPLN. INFO.:	US 1987-1814	19870108
	US 1987-31237	19870326
	US 1987-54193	19870526
	US 1987-54194	19870526
	US 1987-130550	19871215

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 274431 EUROPATFULL EW 199418 FS PS STA B
 TITLE: **Drug delivery** compositions and
 methods.
 Mittel zur Arzneistoffabgabe und Verfahren zu deren
 Herstellung.
 Compositions pour la liberation d'un medicament et leurs
 procedes de fabrication.
 INVENTOR(S): Ecanow, Bernard, 540 Hunter Court, Wilmette Illinois
 60091, US
 PATENT ASSIGNEE(S): QUIXOTE CORPORATION, One East Wacker Drive, Chicago, IL
 60601, US
 PATENT ASSIGNEE NO: 346681
 AGENT: Wain, Christopher Paul et al, A.A. THORNTON & CO.
 Northumberland House 303-306 High Holborn, London WC1V
 7LE, GB
 AGENT NUMBER: 37101
 OTHER SOURCE: EPB1994032 EP 0274431 B1 940504
 SOURCE: Wila-EPS-1994-H18-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R FR; R GB; R IT; R LI; R NL; R
 SE
 PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT
 PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 274431	B1 19940504
'OFFENLEGUNGS' DATE:		19880713
APPLICATION INFO.:	EP 1988-300085	19880107
PRIORITY APPLN. INFO.:	US 1987-1814	19870108
	US 1987-31237	19870326
	US 1987-54193	19870526
	US 1987-54194	19870526
	US 1987-130550	19871215
REFERENCE PAT. INFO.:	EP 83469 A	WO 85-05029 A
	WO 85-05035 A	

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:34:05 ON 23 SEP 2002

=> file caplus uspatful europatful japio medline biosis embase		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.84	0.84

FILE 'CAPLUS' ENTERED AT 10:36:19 ON 23 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 10:36:19 ON 23 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 10:36:19 ON 23 SEP 2002
COPYRIGHT (c) 2002 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 10:36:19 ON 23 SEP 2002
COPYRIGHT (C) 2002 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 10:36:19 ON 23 SEP 2002

FILE 'BIOSIS' ENTERED AT 10:36:19 ON 23 SEP 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 10:36:19 ON 23 SEP 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

=> s transmucosal? and (drug delivery)

4 FILES SEARCHED...

L1 1427 TRANSMUCOSAL? AND (DRUG DELIVERY)

=> s l1 and (sequential or two or multiple)(w)phase?

3 FILES SEARCHED...

L2 57 L1 AND (SEQUENTIAL OR TWO OR MULTIPLE)(W) PHASE?

=> s l2 and pH and (modif? or adjust? or neutral? or acid? or bas? or alkali?)

3 FILES SEARCHED...

L3 43 L2 AND PH AND (MODIF? OR ADJUST? OR NEUTRAL? OR ACID? OR BAS?
OR ALKALI?)

=> s l3 and dissol? and absor?

4 FILES SEARCHED...

L4 33 L3 AND DISSOL? AND ABSOR?

=> s l4 and (coat? or membrane# or matri? or precursor?)

3 FILES SEARCHED...

L5 33 L4 AND (COAT? OR MEMBRANE# OR MATRI? OR PRECURSOR?)

=> s l5 qand (buccal? or sublingual? or gingival? or gastrointestinal? or rectal?
or vaginal? or nasal?)

MISSING OPERATOR L5 QAND

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l5 and (buccal? or sublingual? or gingival? or gastrointestinal? or rectal? or
vaginal? or nasal?)

5 FILES SEARCHED...

L6 33 L5 AND (BUCCAL? OR SUBLINGUAL? OR GINGIVAL? OR GASTROINTESTINAL
? OR RECTAL? OR VAGINAL? OR NASAL?)

=> s 16 and local?
L7 25 L6 AND LOCAL?

=> d 17 1-25 ibib abs

L7 ANSWER 1 OF 25 USPATFULL

ACCESSION NUMBER: 2002:243051 USPATFULL
TITLE: Compositions and methods for the therapy and diagnosis
of ovarian cancer
INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132237	A1	20020919
APPLICATION INFO.:	US 2001-867701	A1	20010529 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	25718	

AB Compositions and methods for the therapy and diagnosis of cancer,
particularly ovarian cancer, are disclosed. Illustrative compositions
comprise one or more ovarian tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly ovarian cancer.

L7 ANSWER 2 OF 25 USPATFULL

ACCESSION NUMBER: 2002:199159 USPATFULL
TITLE: Benzoxazole LPAAT-B inhibitors and uses thereof
INVENTOR(S): Bonham, Lynn, Seattle, WA, UNITED STATES
Klein, J. Peter, Vashon, WA, UNITED STATES
Finney, Robert E., Shoreline, WA, UNITED STATES
Hollenback, David M., Seattle, WA, UNITED STATES
Shaffer, Scott A., Seattle, WA, UNITED STATES
Tang, Norina M., Ann Arbor, WA, UNITED STATES
White, Thayer H., Bellevue, WA, UNITED STATES
Leung, David W., Mercer Island, WA, UNITED STATES
PATENT ASSIGNEE(S): CELL THERAPEUTICS, INC.

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002107269	A1	20020808
APPLICATION INFO.:	US 2001-984889	A1	20011031 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244194P	20001031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: Stephen A. Bent, Foley & Lardner, Washington Harbour,
3000 K Street, N.W., Suite 500, Washington, DC,
20007-5109

NUMBER OF CLAIMS: 30

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Page(s)

LINE COUNT: 2653

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to benzoxazoles and the use thereof to inhibit
lysophosphatidic **acid** acyltransferase .beta. (LPAAT-.beta.)
activity. The invention further relates to methods of treating cancer
using said benzoxazoles. The invention also relates to methods for
screening for LPAAT-.beta. activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 25 USPATFULL

ACCESSION NUMBER: 2002:192124 USPATFULL

TITLE: LPAAT-B inhibitors and uses thereof

INVENTOR(S): Bonham, Lynn, Seattle, WA, UNITED STATES

Klein, J. Peter, Vashon, WA, UNITED STATES

Finney, Robert E., Shoreline, WA, UNITED STATES

Hollenback, David M., Seattle, WA, UNITED STATES

Shaffer, Scott A., Seattle, WA, UNITED STATES

Tang, Norina M., Ann Arbor, MI, UNITED STATES

White, Thayer H., Bellevue, WA, UNITED STATES

Leung, David W., Mercer Island, WA, UNITED STATES

PATENT ASSIGNEE(S): CELL THERAPEUTICS, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002103195	A1	20020801
APPLICATION INFO.:	US 2001-984888	A1	20011031 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244195P	20001031 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Stephen A. Bent, Foley & Lardner, Washington Harbour,
3000 K Street, N.W., Suite 500, Washington, DC,
20007-5109

NUMBER OF CLAIMS: 39

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 21 Drawing Page(s)

LINE COUNT: 1634

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to triazines and the use thereof to inhibit
lysophosphatidic **acid** acyltransferase .beta. (LPAAT-.beta.)
activity. The invention further relates to methods of treating cancer
using said triazines. The invention also relates to methods for
screening for LPAAT-.beta. activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 25 USPATFULL

ACCESSION NUMBER: 2002:148306 USPATFULL

TITLE: **Multiple phase** cross-linked

compositions and uses thereof

INVENTOR(S): Stein, Stanley, East Brunswick, NJ, UNITED STATES

Qiu, Bo, East Brunswick, NJ, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2002076443 A1 20020620
APPLICATION INFO.: US 2001-883842 A1 20010618 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-212511P	20000619 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KLAUBER & JACKSON, 411 HACKENSACK AVENUE, HACKENSACK, NJ, 07601	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1908	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to pharmaceutical compositions, and method for preparing pharmaceutical compositions, comprising a cross-linked **matrix** physically entrapping at least one therapeutic agent. The **matrix** may comprise one or more phases in addition to an aqueous phase, such as a solid and/or oil phase. The **matrix** of the invention has at least one controlled release in-vivo kinetic profile, and may have additional profiles for the same agent. The **matrix** may also comprise more than one therapeutic agent, and each additional therapeutic agent may have one or more controlled release in-vivo kinetic profile.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 25 USPATFULL

ACCESSION NUMBER: 2002:63527 USPATFULL
TITLE: Hydrophilic ampholytic polymer
INVENTOR(S): Galleguillos, Ramiro, Hudson, OH, United States
Budrevich, Jodi A., Cuyahoga Falls, OH, United States
Chiarelli, Joseph A., Broadview Heights, OH, United States
Bathina, Harinath B., Hudson, OH, United States
Amjad, Zahid, Brecksville, OH, United States
PATENT ASSIGNEE(S): PMD Holdings Corp., Brecksville, OH, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6361768	B1	20020326
APPLICATION INFO.:	US 1998-222495		19981229 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Sheikh, Humera N.		
LEGAL REPRESENTATIVE:	Moxon, II, George W., Hudak & Shunk Co., L.P.A.		
NUMBER OF CLAIMS:	54		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	2061		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel hydrophilic ampholytic polymer synthesized by reacting polymerizable amino and carboxy functional ethylenically unsaturated monomers, together with a non-ionic hydrophilic monomer, to provide a polymer having a glass transition temperature (T.sub.g) above about 50.degree. C., and optionally hydrophobic monomer(s), and cross-linking monomer(s). The copolymer is precipitated from a polymerization media which includes a suitable organic solvent. The resulting copolymer is in the form of a fine powder, with submicron particle size. As such it is suitable for use as a thickener or rheology **modifier** in personal care formulations, such as shampoo, conditioner, and the like,

as a bioadhesive, and for other pharmaceutical applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 25 USPATFULL

ACCESSION NUMBER: 2002:60703 USPATFULL
TITLE: Cationic diagnostic, imaging and therapeutic agents
associated with activated vascular sites
INVENTOR(S): Schulze, Brita, Walchensee, GERMANY, FEDERAL REPUBLIC
OF
Sauer, Birgitta, Penzberg, GERMANY, FEDERAL REPUBLIC OF
Dellian, Marc, Munich, GERMANY, FEDERAL REPUBLIC OF
Michaelis, Uwe, Weilheim, GERMANY, FEDERAL REPUBLIC OF
Teifel, Michael, Penzberg, GERMANY, FEDERAL REPUBLIC OF
Naujoks, Kurt W., Penzberg, GERMANY, FEDERAL REPUBLIC
OF
Biro, Claudia, Muehldorf, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002034537	A1	20020321
APPLICATION INFO.:	US 2001-847538	A1	20010503 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201673P	20000503 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN, LEWIS & BOCKIUS, 1800 M STREET NW, WASHINGTON, DC, 20036-5869	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	2561	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and associated compositions are described for enhancing the
selective delivery of therapeutic, diagnostic and imaging agents to
activated vascular sites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 25 USPATFULL

ACCESSION NUMBER: 2002:32528 USPATFULL
TITLE: Targeted angiogenesis
INVENTOR(S): Levine, Arnold J., New York, NY, UNITED STATES
Mitterer, Artur, Orth, Donau, AUSTRIA
Falkner, Falko-Guenter, Orth, Donau, AUSTRIA
Scheifflinger, Friedrich, Vienna, AUSTRIA
Dorner, Friedrich, Vienna, AUSTRIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019350	A1	20020214
APPLICATION INFO.:	US 2001-782650	A1	20010212 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-327045, filed on 7 Jun 1999, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2479		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compositions, methods, and gene therapy reagents to promote or to inhibit angiogenesis in the treatment of peripheral vascular or cardiovascular diseases, utilizing a chimeric molecule comprising an angiogenic factor linked to a targeting molecule that specifically binds to a vascular endothelium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 25 USPATFULL

ACCESSION NUMBER: 2002:21845 USPATFULL
TITLE: Compositions and methods for improved delivery of lipid regulating agents
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002012680	A1	20020131
	US 6451339	B2	20020917
APPLICATION INFO.:	US 2001-898553	A1	20010702 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025		
NUMBER OF CLAIMS:	140		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	3604		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to triglyceride-free pharmaceutical compositions for delivery of hydrophobic therapeutic agents. Compositions of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the surfactants containing the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 25 USPATFULL

ACCESSION NUMBER: 2001:237457 USPATFULL
TITLE: **Nasal drug delivery**
composition
INVENTOR(S): Davis, Stanley Stewart, Nottingham, Great Britain
Illum, Lisbeth, Nottingham, Great Britain
PATENT ASSIGNEE(S): West Pharmaceutical Services Drug Delivery & Clinical Research Centre, Ltd (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001055569	A1	20011227
APPLICATION INFO.:	US 2001-841228	A1	20010424 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-GB3489, filed on 21 Oct 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-23246	19981024
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE
SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA,
PA, 19103

NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 397

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a composition comprising an oil-in-water
emulsion and a drug **dissolved** in the emulsion. The oil phase
comprises a hydroxylated oil, particularly a hydroxylated vegetable oil.
The preferred hydroxylated vegetable oil is castor oil.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 25 USPATFULL

ACCESSION NUMBER: 2001:217985 USPATFULL
TITLE: Infrared thermography and methods of use
INVENTOR(S): Marek, Przemyslaw A., Bolton, MA, United States
Trocha, Andzrej M., Billerica, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001046471	A1	20011129
APPLICATION INFO.:	US 2001-850081	A1	20010508 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-202935P	20000509 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EDWARD D GRIEFF, HALE & DORR LLP, 1455 PENNSYLVANIA AVE, NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	99	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	2687	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes rapid noninvasive methods for measuring
vasodilation or changes in blood flow in a patient following
administration of at least one compound that donates, transfers or
releases nitric oxide, elevates endogenous levels of endothelium-derived
relaxing factor, stimulates endogenous synthesis of nitric oxide or is a
substrate for nitric oxide synthase and/or at least one vasoactive
agent. The method comprises the administration of at least one compound
that donates, transfers or releases nitric oxide, elevates endogenous
levels of endothelium-derived relaxing factor, stimulates endogenous
synthesis of nitric oxide or is a substrate for nitric oxide synthase
and/or at least one vasoactive agent to the patient followed by
monitoring the temperature change of an area of interest using infrared
thermography. The present invention provides methods for diagnosing
diseases or disorders related to vasodilation and changes in blood flow,
such as, sexual dysfunction, Raynaud's syndrome, inflammation,
hypertension, **gastrointestinal** disorders and central nervous
system disorders. The sexual dysfunction is preferably female sexual
dysfunction and female sexual arousal. The vasoactive agents include
potassium channel activators, calcium channel blockers,
.alpha.-adrenergic receptor antagonists, .beta.-blockers,
phosphodiesterase inhibitors, adenosine, ergot alkaloids, vasoactive
intestinal peptides, prostaglandins, dopamine agonists, opioid
antagonists, endothelin antagonists and thromboxane inhibitors. The
present invention can also be used to screen and identify drug
candidates for treating diseases, disorders and conditions resulting
from vasodilation or changes in blood flow. The present invention also
describes compositions comprising at least one S-nitrosothiol compound

for diagnosing, monitoring and/or treating female sexual dysfunctions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 25 USPATFULL

ACCESSION NUMBER: 2001:162866 USPATFULL
TITLE: Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, United States
Chen, Feng-Jing, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6294192	B1	20010925
APPLICATION INFO.:	US 1999-258654		19990226 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Channavajjala, Lakshmi		
LEGAL REPRESENTATIVE:	Reed, Dianne E. Reed & Associates		
NUMBER OF CLAIMS:	74		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	3094		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to triglyceride-free pharmaceutical compositions for delivery of hydrophobic therapeutic agents. Compositions of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the surfactants containing the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 25 USPATFULL

ACCESSION NUMBER: 2001:116589 USPATFULL
TITLE: Oral **transmucosal** drug dosage using solid solution
INVENTOR(S): Zhang, Hao, Salt Lake City, UT, United States
Croft, Jed, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Anesta Corporation, Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6264981	B1	20010724
APPLICATION INFO.:	US 1999-428071		19991027 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Azpuru, Carlos		
LEGAL REPRESENTATIVE:	Kirton & McConkie, Krieger, Michael F.		
NUMBER OF CLAIMS:	55		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1057		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed toward formulation and method for oral **transmucosal** delivery of a pharmaceutical. The invention provides a drug formulation comprising a solid pharmaceutical agent in

solid solution with a **dissolution** agent. The formulation is administered into a patient's oral cavity, delivering the pharmaceutical agent by **absorption** through a patient's oral mucosal tissue. The formulation and method provide for improved oral mucosal delivery of the pharmaceutical agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 25 USPATFULL

ACCESSION NUMBER: 2001:93139 USPATFULL
TITLE: Metal/thiol biocides
INVENTOR(S): Domenico, Philip, Elmhurst, NY, United States
PATENT ASSIGNEE(S): Winthrop University Hospital, Mineola, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6248371	B1	20010619
APPLICATION INFO.:	US 2000-543880		20000406 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-960031, filed on 28 Oct 1997, now patented, Pat. No. US 6086921 Continuation-in-part of Ser. No. US 1997-883584, filed on 26 Jun 1997, now patented, Pat. No. US 5928671 Continuation of Ser. No. US 1995-428464, filed on 25 Apr 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Spivack, Phyllis G.		
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen, LLP		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	2322		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for administering a composition comprising bismuth and a thiol-containing complexing agent as a bacteriocidal, bacteriostatic, antifungal or antiviral agent are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 25 USPATFULL

ACCESSION NUMBER: 2001:36919 USPATFULL
TITLE: Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
INVENTOR(S): Rath, Ramesh C., Salt Lake City, UT, United States
Zentner, Gaylen M., Salt Lake City, UT, United States
Jeong, Byeongmoon, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): MacroMed, Inc., Sandy, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6201072	B1	20010313
APPLICATION INFO.:	US 1999-396589		19990915 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-164865, filed on 1 Oct 1998, now patented, Pat. No. US 6117949 Continuation-in-part of Ser. No. US 1997-943167, filed on 3 Oct 1997, now patented, Pat. No. US 6004573		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Truong, Duc		
LEGAL REPRESENTATIVE:	Thorpe North & Western LLP		
NUMBER OF CLAIMS:	77		

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A water soluble, biodegradable ABA- or BAB-type tri-block polymer is disclosed that is made up of a major amount of a hydrophobic A polymer block made of a biodegradable polyester and a minor amount of a hydrophilic polyethylene glycol (PEG) B polymer block, having an overall average molecular weight of between about 2000 and 4990, and that possesses reverse thermal gelation properties. Effective concentrations of the tri-block polymer and a drug may be uniformly contained in an aqueous phase to form a **drug delivery** composition. At temperatures below the gelation temperature of the tri-block polymer the composition is a liquid and at temperatures at or above the gelation temperature the composition is a gel or semi-solid. The composition may be administered to a warm-blooded animal as a liquid by parenteral, ocular, topical, inhalation, transdermal, **vaginal**, transurethral, **rectal**, **nasal**, oral, pulmonary or aural delivery means and is a gel at body temperature. The composition may also be administered as a gel. The drug is released at a controlled rate from the gel which biodegrades into non-toxic products. The release rate of the drug may be **adjusted** by changing various parameters such as hydrophobic/hydrophilic component content, polymer concentration, molecular weight and polydispersity of the tri-block polymer. Because the tri-block polymer is amphiphilic, it functions to increase the solubility and/or stability of drugs in the composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 25 USPATFULL

ACCESSION NUMBER: 2000:121592 USPATFULL
TITLE: Biodegradable low molecular weight triblock poly
(lactide-co-glycolide) polyethylene glycol copolymers
having reverse thermal gelation properties
INVENTOR(S): Rathi, Ramesh C., Salt Lake City, UT, United States
Zentner, Gaylen M., Salt Lake City, UT, United States
Jeong, Byeongmoon, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Macromed, Inc., Salt Lake City, UT, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117949		20000912
APPLICATION INFO.:	US 1998-164865		19981001 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Truong, Duc		
LEGAL REPRESENTATIVE:	Thorpe, North & Western, LLP		
NUMBER OF CLAIMS:	69		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	1274		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A water soluble biodegradable ABA- or BAB-type triblock polymer is disclosed that is made up of a major amount of a hydrophobic polymer made of a poly(lactide-co-glycolide) copolymer or poly(lactide) polymer as the A-blocks and a minor amount of a hydrophilic polyethylene glycol polymer B-block, having an overall weight average molecular weight of between about 2000 and 4990, and that possesses reverse thermal gelation properties. Effective concentrations of the triblock polymer and a drug may be uniformly contained in an aqueous phase to form a **drug delivery** composition. At temperatures below the gelation temperature of the triblock polymer the composition is a liquid and at temperatures at or above the gelation temperature the composition is a

gel or semi-solid. The composition may be administered to a warm-blooded animal as a liquid by parenteral, ocular, topical, inhalation, transdermal, **vaginal**, transurethral, **rectal**, **nasal**, oral, pulmonary or aural delivery means and is a gel at body temperature. The composition may also be administered as a gel. The drug is released at a controlled rate from the gel which biodegrades into non-toxic products. The release rate of the drug may be **adjusted** by changing various parameters such as hydrophobic/hydrophilic component content, polymer concentration, molecular weight and polydispersity of the triblock polymer. Because the triblock polymer is amphiphilic, it functions to increase the solubility and/or stability of drugs in the composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 25 USPATFULL

ACCESSION NUMBER: 2000:87752 USPATFULL
 TITLE: Metal/thiol biocides
 INVENTOR(S): Domenico, Philip, Elmhurst, NY, United States
 PATENT ASSIGNEE(S): Wintrop-University Hospital, Mineola, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 6086921		20000711
APPLICATION INFO.:	US 1997-960031		19971028 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-883584, filed on 26 Jun 1997, now patented, Pat. No. US 5928671 which is a continuation of Ser. No. US 1995-428464, filed on 25 Apr 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spivack, Phyllis G.		
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen, LLP		
NUMBER OF CLAIMS:	41		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	2588		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition described wherein bismuth is chelated by a complexing agent such as a pyrithione or certain other thiol compounds in the form a metal:complexing agent complex. Methods for using the composition as a bacteriocidal, bacteriostatic, antibiofilm, antifungal, and antiviral agent and as a disinfectant and preservative are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 25 USPATFULL

ACCESSION NUMBER: 2000:9947 USPATFULL
 TITLE: Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
 INVENTOR(S): Kun, Ernest, Mill Valley, CA, United States
 Mendeleyev, Jerome, Tiburon, CA, United States
 PATENT ASSIGNEE(S): Octamer, Inc., Berkeley, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 6017958		20000125
APPLICATION INFO.:	US 1997-833272		19970403 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-655267, filed on 4 Jun 1996, now patented, Pat. No. US 5736576		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

PRIMARY EXAMINER: Goldberg, Jerome D.
LEGAL REPRESENTATIVE: Halluin, Albert P.Howrey & Simon
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 2491

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for treating cancer, particularly malignant tumors, with thyroxine analogues having no significant hormonal activity. A thyroxine analogue is administered to an afflicted mammal in an amount effective to cause depression or regression of malignant tumor growth or to treat cancer. Particularly preferred thyroxine analogues are those capable of causing about 35 percent or more inhibition of initial velocity of microtubule protein assembly in vitro.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 25 USPATFULL

ACCESSION NUMBER: 1999:155235 USPATFULL
TITLE: Method for preparing biphasic multilamellar lipid vesicles
INVENTOR(S): Foldvari, Marianna, Saskatoon, Canada
PATENT ASSIGNEE(S): PharmaDerm Laboratories, Ltd., Saskatchewan, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5993851		19991130
APPLICATION INFO.:	US 1998-42097		19980313 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-872068, filed on 10 Jun 1997 which is a continuation of Ser. No. US 1995-507923, filed on 27 Jul 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-98102, filed on 28 Jul 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kishore, Gollamudi S.		
LEGAL REPRESENTATIVE:	Mohr, Judy M.Dehlinger & Associates		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	2036		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A biphasic multilamellar lipid vesicle comprising a plurality of spaced apart lipid bilayers that include a liposome-forming component and optionally a biologically active agent entrapped within the lipid bilayers. The lipid vesicle also comprises peripheral aqueous solution compartments formed between the lipid bilayers and a central lipophilic core compartment substantially at the center of the multilamellar lipid vesicle.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 25 USPATFULL

ACCESSION NUMBER: 1999:96436 USPATFULL
TITLE: Responsive polymer networks and methods of their use
INVENTOR(S): Bromberg, Lev, Lynn, MA, United States
Lupton, Elmer Cornelius (E.C.), Boston, MA, United States
Schiller, Matthew E., Waltham, MA, United States
Timm, Mary Jo (M.J.), Taunton, MA, United States
McKinney, George, Chestnut Hill, MA, United States
PATENT ASSIGNEE(S): MedLogic Global Corporation, Colorado Springs, CO,

United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5939485		19990817
APPLICATION INFO.:	US 1996-580986		19960103 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-312P	19950619 (60)
	US 1995-8053P	19951030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Lipman, Bernard	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 15 Drawing Page(s)	
LINE COUNT:	2688	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A responsive polymer network exhibiting the property of reversible gelation in response to a change in an environmental stimulus is provided. The aqueous solution of the network polymer, comprises about 0.01 to 20 wt % by weight of a responsive component and about 0.01 to 20 wt % by weight of a structural component capable of supporting and interacting with the responsive component. The aqueous composition exhibits at least a five-fold increase in viscosity upon gelation. The gelation may be triggered by a change in an environmental stimulus, such as temperature, pH and ionic strength.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 25 USPATFULL

ACCESSION NUMBER: 1999:92323 USPATFULL

TITLE: **Nasal drug delivery**
composition containing nicotine

INVENTOR(S): Illum, Lisbeth, The Park, United Kingdom

PATENT ASSIGNEE(S): Danbiosyst UK Limited, Nottingham, United Kingdom
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5935604		19990810
	WO 9427576		19941208
APPLICATION INFO.:	US 1996-553401		19960701 (8)
	WO 1994-GB1092		19940520
			19960701 PCT 371 date
			19960701 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1993-10412	19930520
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kulkosky, Peter F.	
LEGAL REPRESENTATIVE:	Arnall Golden & Gregory, LLP	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	812	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a **nasal drug delivery** composition comprising nicotine or a pharmacologically-acceptable salt or derivative thereof wherein the

composition is adapted to delivery a pulse of nicotine for rapid **absorption** and a controlled release of nicotine for subsequent sustained **absorption**. The controlled release phase can be achieved by providing an ion-exchange material which will form a complex with the nicotine. The ion-exchange material may be a polymeric material such as a polysaccharide, or may be in the form of bioadhesive ion-exchange microspheres. The pulse release can be achieved by overloading the ion-exchange material with nicotine so that the composition contains some excess nicotine for immediate release and **absorption**. Alternatively, some nicotine may be associated with a non ion-exchange material which will release the nicotine immediately on contact with the **nasal** mucosa, for example non-ion-exchange bioadhesive microspheres.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 25 USPATFULL

ACCESSION NUMBER: 1999:60998 USPATFULL
 TITLE: Intra-oral antioxidant preparations
 INVENTOR(S): Hersh, Theodore, Atlanta, GA, United States
 PATENT ASSIGNEE(S): Thione International, Inc., Atlanta, GA, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5906811		19990525
APPLICATION INFO.:	US 1997-884282		19970627 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kulkosky, Peter F.		
LEGAL REPRESENTATIVE:	Wittenberg, Malcolm B.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1356		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The combination of several synergistic antioxidants, enzymatic co-factors and amino **acids** in appropriate delivery vehicles employed in aerosol carriers, mist and pump oral sprays, solutions, such as oral irrigators, mouth rinses and mouthwashes, or gels and solid compositions as a means of preventing and ameliorating signs and symptoms and complications to the oro-pharyngeal cavity and mouth including **buccal** mucosa, gums and tongue and the upper respiratory tract from damage caused by free radical species induced by tobacco smoke, smokeless tobacco, ingested or chewed noxious, malodorous or harmful substances and other inhaled environmental pollutants and particulate matter, including tobacco to secondary smokers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 25 USPATFULL

ACCESSION NUMBER: 1998:162029 USPATFULL
 TITLE: Biphasic multilamellar lipid vesicles
 INVENTOR(S): Foldvari, Marianna, Saskatoon, Canada
 PATENT ASSIGNEE(S): PharmaDerm Laboratories Ltd., Saskatchewan, Canada
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5853755		19981229
APPLICATION INFO.:	US 1997-872068		19970610 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-507923, filed on 27 Jul 1995, now abandoned And a continuation-in-part of Ser. No. US 1993-98102, filed on 28 Jul 1993, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kishore, Gollamudi S.
LEGAL REPRESENTATIVE: Mohr, Judy M. Dehlinger & Associates
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1938

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A biphasic multilamellar lipid vesicle comprising a plurality of spaced apart lipid bilayers that include a liposome-forming component and optionally a biologically active agent entrapped within the lipid bilayers. The lipid vesicle also comprises peripheral aqueous solution compartments formed between the lipid bilayers and a central lipophilic core compartment substantially at the center of the multilamellar lipid vesicle.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 25 USPATFULL

ACCESSION NUMBER: 90:79697 USPATFULL
TITLE: **Drug delivery** compositions and methods

INVENTOR(S): Ecanow, Bernard, Wilmette, IL, United States
PATENT ASSIGNEE(S): Medaphore, Inc., Wilmette, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4963367		19901016
APPLICATION INFO.:	US 1987-130550		19871215 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1985-711066, filed on 12 Mar 1985, now abandoned And Ser. No. US 1985-710048, filed on 11 Mar 1985, now abandoned And Ser. No. US 1986-835550, filed on 3 Mar 1986, now patented, Pat. No. US 4849405 And Ser. No. US 1986-896844, filed on 14 Aug 1986, now abandoned And Ser. No. US 1987-1314, filed on 8 Jan 1987, now patented, Pat. No. US 4794000 And Ser. No. US 1987-31237, filed on 26 Mar 1987, now patented, Pat. No. US 4914084 And Ser. No. US 1987-54193, filed on 26 May 1987, now abandoned And Ser. No. US 1987-54194, filed on 26 May 1987, now abandoned And Ser. No. US 1985-811675, filed on 20 Dec 1985, now patented, Pat. No. US 4738952 which is a continuation-in-part of Ser. No. US 1984-604476, filed on 27 Apr 1984, now abandoned, said Ser. No. 835550 which is a continuation-in-part of Ser. No. US 1984-604483, filed on 9 May 1984, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lovering, Richard D.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Bicknell
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1,27
LINE COUNT: 2363

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Drug delivery** compositions yeild new and unexpected degrees of stabilization, solubilization and delivery of incorporated medicaments, drugs, or other physiologically-active compounds. The compositions enable administration of drugs and other medically useful compounds via a variety of routes. More particularly, a **drug delivery** system or composition including one or more monomeric or polymerized surface active agents allows for rapid

dissolution and smooth liberation of any desired incorporated drug or combinations, and the method of preparing the drug composition. In one embodiment, the physiologically-active compound is encapsulated by a coacervate-derived film, and the finished product is suitable for **transmucosal** administration. Other formulations of this invention may be administered via inhalation, oral, parenteral and by transdermal and **transmucosal** routes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 25 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 697858 EUROPATFULL EW 199743 FS PS
TITLE: **NASAL DRUG DELIVERY**
COMPOSITION CONTAINING NICOTINE.
ARZNEIMITTELZUSAMMENSETZUNG FUEr VERABREICHUNG VON
NIKOTIN DURCH DIE NASE.
COMPOSITION D'ADMINISTRATION PAR VOIE **NASALE**
D'UN MEDICAMENT, CONTENANT DE LA NICOTINE.
INVENTOR(S): ILLUM, Lisbeth, 19 Cavendish Crescent North, The Park,
Nottingham NG7 1BA, GB
PATENT ASSIGNEE(S): DANBIOSYST UK LIMITED, Albert Einstein Centre,
Highfields Science Park, Nottingham NG7 2TN, GB
PATENT ASSIGNEE NO: 1161683
AGENT: Bassett, Richard Simon et al, ERIC POTTER & CLARKSON St.
Mary's Court St. Mary's Gate, Nottingham NG1 1LE, GB
AGENT NUMBER: 52833
OTHER SOURCE: EPB1997068 EP 0697858 B1 971022
SOURCE: Wila-EPS-1997-H43-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GR; R IE; R
IT; R LI; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale
Anmeldung)
PATENT INFORMATION:
PATENT NO KIND DATE

EP 697858 B1 19971022
'OFFENLEGUNGS' DATE: 19960228
APPLICATION INFO.: EP 1994-915637 19940520
PRIORITY APPLN. INFO.: GB 1993-10412 19930520
RELATED DOC. INFO.: WO 94-GB1092 940520 INTAKZ
WO 9427576 941208 INTPNR
REFERENCE PAT. INFO.: EP 148749 A WO 93-12764 A
REF. NON-PATENT-LIT.: Whistler et al. "Industrial Gums" Academic Press (1993),
pages 537 and 548-551 Sigma Catalogue (1995), page 1705

L7 ANSWER 25 OF 25 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 274431 EUROPATFULL EW 198828 FS OS STA B
TITLE: **Drug delivery** compositions and
methods.
Mittel zur Arzneistoffabgabe und Verfahren zu deren
Herstellung.
Compositions pour la liberation d'un medicament et leurs
procedes de fabrication.
INVENTOR(S): Ecanow, Bernard, 540 Hunter Court, Wilmette Illinois
60091, US
PATENT ASSIGNEE(S): MEDAPHORE INC., 540 Hunter Court, Wilmette, IL 60091, US

PATENT ASSIGNEE NO: 397830
 AGENT: Wain, Christopher Paul, et al, A.A. THORNTON & CO.
 Northumberland House 303-306 High Holborn, London WC1V
 7LE, GB
 OTHER SOURCE: ESP1988025 EP 0274431 A2 880713
 SOURCE: Wila-EPZ-1988-H28-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R FR; R GB; R IT; R LI; R NL; R
 SE
 PATENT INFO.PUB.TYPE: EPA2 EUROPÄISCHE PATENTANMELDUNG
 PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 274431	A2	19880713
'OFFENLEGUNGS' DATE:			19880713
APPLICATION INFO.:	EP 1988-300085		19880107
PRIORITY APPLN. INFO.:	US 1987-1814		19870108
	US 1987-31237		19870326
	US 1987-54193		19870526
	US 1987-54194		19870526
	US 1987-130550		19871215

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 274431 EUROPATFULL EW 199418 FS PS STA B
 TITLE: **Drug delivery** compositions and
 methods.
 Mittel zur Arzneistoffabgabe und Verfahren zu deren
 Herstellung.
 Compositions pour la liberation d'un medicament et leurs
 procedes de fabrication.
 INVENTOR(S): Ecanow, Bernard, 540 Hunter Court, Wilmette Illinois
 60091, US
 PATENT ASSIGNEE(S): QUIXOTE CORPORATION, One East Wacker Drive, Chicago, IL
 60601, US
 PATENT ASSIGNEE NO: 346681
 AGENT: Wain, Christopher Paul et al, A.A. THORNTON & CO.
 Northumberland House 303-306 High Holborn, London WC1V
 7LE, GB
 AGENT NUMBER: 37101
 OTHER SOURCE: EPB1994032 EP 0274431 B1 940504
 SOURCE: Wila-EPS-1994-H18-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R FR; R GB; R IT; R LI; R NL; R
 SE
 PATENT INFO.PUB.TYPE: EPB1 EUROPÄISCHE PATENTSCHRIFT
 PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 274431	B1	19940504
'OFFENLEGUNGS' DATE:			19880713
APPLICATION INFO.:	EP 1988-300085		19880107
PRIORITY APPLN. INFO.:	US 1987-1814		19870108
	US 1987-31237		19870326
	US 1987-54193		19870526
	US 1987-54194		19870526
	US 1987-130550		19871215
REFERENCE PAT. INFO.:	EP 83469 A		WO 85-05029 A
	WO 85-05035 A		